Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

James Dirk Iglehart, M.D.

TitleAnne E. Dyson Professor in Women's Cancers
InstitutionDana-Farber Cancer Institute
DepartmentSurgery
AddressDana Farber Cancer Institute
Room 822, Smith Building
44 Binney St
Boston MA 02115
Phone617/732-6437
Fax617/632-3709

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC. Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations. PLoS One. 2013; 8(11):e80023.
    View in: PubMed
  2. Kochupurakkal BS, Iglehart JD. Nourseothricin N-acetyl transferase: a positive selection marker for Mammalian cells. PLoS One. 2013; 8(7):e68509.
    View in: PubMed
  3. Calkins AS, Iglehart JD, Lazaro JB. DNA damage-induced inhibition of rRNA synthesis by DNA-PK and PARP-1. Nucleic Acids Res. 2013 Aug 1; 41(15):7378-86.
    View in: PubMed
  4. Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come SE. Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. PLoS One. 2013; 8(5):e64225.
    View in: PubMed
  5. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD, Matulonis UA. Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012 Oct 15; 18(20):5806-15.
    View in: PubMed
  6. Dominici L, Liao GS, Brock J, Iglehart JD, Lotfi P, Meyer J, Pandalai P, Golshan M. Large needle core biopsy of atypical ductal hyperplasia: results of surgical excision. Breast J. 2012 Sep; 18(5):506-8.
    View in: PubMed
  7. Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110a and p110ß isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012 Jul 15; 26(14):1573-86.
    View in: PubMed
  8. Richardson AL, Iglehart JD. BEAMing up personalized medicine: mutation detection in blood. Clin Cancer Res. 2012 Jun 15; 18(12):3209-11.
    View in: PubMed
  9. Adelmant G, Calkins AS, Garg BK, Card JD, Askenazi M, Miron A, Sobhian B, Zhang Y, Nakatani Y, Silver PA, Iglehart JD, Marto JA, Lazaro JB. DNA ends alter the molecular composition and localization of Ku multicomponent complexes. Mol Cell Proteomics. 2012 Aug; 11(8):411-21.
    View in: PubMed
  10. Iglehart JD, Valero MG. Commentary on "The role of the breast cancer surgeon in personalized cancer care: clinical utility of the 21-gene assay". Am J Surg. 2012 Jun; 203(6):759-60.
    View in: PubMed
  11. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012 Apr; 2(4):366-75.
    View in: PubMed
  12. Li Y, Iglehart JD, Richardson AL, Wang ZC. The amplified cancer gene LAPTM4B promotes tumor growth and tolerance to stress through the induction of autophagy. Autophagy. 2012 Feb 1; 8(2):273-4.
    View in: PubMed
  13. Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC, Richardson AL. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res. 2011 Dec 15; 71(24):7481-9.
    View in: PubMed
  14. Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.
    View in: PubMed
  15. Westover KD, Westover MB, Winer EP, Richardson AL, Iglehart JD, Punglia RS. Should a sentinel node biopsy be performed in patients with high-risk breast cancer? Int J Breast Cancer. 2011; 2011:973245.
    View in: PubMed
  16. Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, Lanahan AA, Taylor JM, Holmes C, Hahn WC, Zhao JJ, Iglehart JD, Quackenbush J. Therapeutic implications of GIPC1 silencing in cancer. PLoS One. 2010; 5(12):e15581.
    View in: PubMed
  17. Birdwell RL, Mountford CE, Iglehart JD. Molecular imaging of the breast. Radiol Clin North Am. 2010 Sep; 48(5):1075-88.
    View in: PubMed
  18. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, Park SY, Cho EY, Lewis G, Kehoe S, Iglehart JD, Dillon D, Allred DC, Macconaill L, Gelman R, Polyak K. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res. 2010 Jul 15; 70(14):5674-8.
    View in: PubMed
  19. Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell. 2010 May 28; 38(4):512-23.
    View in: PubMed
  20. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL, Wang ZC. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010 Feb; 16(2):214-8.
    View in: PubMed
  21. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3.
    View in: PubMed
  22. Birdwell RL, Mountford CE, Iglehart JD. Molecular imaging of the breast. AJR Am J Roentgenol. 2009 Aug; 193(2):367-76.
    View in: PubMed
  23. Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, Hahn WC, Zhao JJ. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal. 2009; 2(80):ra35.
    View in: PubMed
  24. Iglehart JD, Silver DP. Synthetic lethality--a new direction in cancer-drug development. N Engl J Med. 2009 Jul 9; 361(2):189-91.
    View in: PubMed
  25. Dejmek J, Iglehart JD, Lazaro JB. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res. 2009 Apr; 7(4):581-91.
    View in: PubMed
  26. Nunes RA, Li X, Kang SP, Burstein H, Roberts L, Carney W, Blackwell K, Ryan P, Borges V, Iglehart JD, Friedman P, Harris LN. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10.
    View in: PubMed
  27. Rosner B, Colditz GA, Iglehart JD, Hankinson SE. Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer: prospective data from the Nurses' Health Study. Breast Cancer Res. 2008; 10(4):R55.
    View in: PubMed
  28. Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.
    View in: PubMed
  29. You F, Roberts LA, Kang SP, Nunes RA, Dias C, Iglehart JD, Solomon NA, Friedman PN, Harris LN. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells. J Hematol Oncol. 2008; 1:2.
    View in: PubMed
  30. Tamimi RM, Brugge JS, Freedman ML, Miron A, Iglehart JD, Colditz GA, Hankinson SE. Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res. 2008 Jan 1; 68(1):18-21.
    View in: PubMed
  31. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007 Nov 1; 96(6):474-80.
    View in: PubMed
  32. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Serial transplantation of NMU-induced rat mammary tumors: a model of human breast cancer progression. Int J Cancer. 2007 Aug 1; 121(3):474-85.
    View in: PubMed
  33. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell. 2007 Aug; 12(2):160-70.
    View in: PubMed
  34. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther. 2007 Jul; 6(7):1973-82.
    View in: PubMed
  35. Qiao M, Iglehart JD, Pardee AB. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer Res. 2007 Jun 1; 67(11):5293-9.
    View in: PubMed
  36. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat. 2008 Mar; 108(2):191-201.
    View in: PubMed
  37. Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
    View in: PubMed
  38. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol. 2006 Dec; 209(3):645-52.
    View in: PubMed
  39. Chang SB, Miron P, Miron A, Iglehart JD. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells. J Surg Res. 2007 Mar; 138(1):37-44.
    View in: PubMed
  40. Shi Q, Harris LN, Lu X, Li X, Hwang J, Gentleman R, Iglehart JD, Miron A. Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res. 2006 Nov; 5(11):2947-55.
    View in: PubMed
  41. Golshan M, Miron A, Nixon AJ, Garber JE, Cash EP, Iglehart JD, Harris JR, Wong JS. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg. 2006 Jul; 192(1):58-62.
    View in: PubMed
  42. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat. 2006 Jun; 97(3):301-9.
    View in: PubMed
  43. Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics. 2006; 7:197.
    View in: PubMed
  44. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006 Feb; 9(2):121-32.
    View in: PubMed
  45. Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD. Crossroads of estrogen receptor and NF-kappaB signaling. Sci STKE. 2005 Jun 14; 2005(288):pe27.
    View in: PubMed
  46. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005 May; 91(2):179-86.
    View in: PubMed
  47. Chan MM, Lu X, Merchant FM, Iglehart JD, Miron PL. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis. 2005 Aug; 26(8):1343-53.
    View in: PubMed
  48. Ganesan S, Richardson AL, Wang ZC, Iglehart JD, Miron A, Feunteun J, Silver D, Livingston DM. Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb Symp Quant Biol. 2005; 70:93-7.
    View in: PubMed
  49. Chan MM, Iglehart JD. Viral oncolysis: tumor-tailored therapy. Curr Surg. 2005 Jan-Feb; 62(1):25-30.
    View in: PubMed
  50. Matros E, Wang ZC, Richardson AL, Iglehart JD. Genomic approaches in cancer biology. Surgery. 2004 Sep; 136(3):511-8.
    View in: PubMed
  51. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004 Jul 6; 101(27):10137-42.
    View in: PubMed
  52. Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004 Jan 1; 64(1):64-71.
    View in: PubMed
  53. Bluman LG, Rimer BK, Regan Sterba K, Lancaster J, Clark S, Borstelmann N, Iglehart JD, Winer EP. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology. 2003 Jul-Aug; 12(5):410-27.
    View in: PubMed
  54. Nahta R, Iglehart JD, Kempkes B, Schmidt EV. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res. 2002 Apr 15; 62(8):2267-71.
    View in: PubMed
  55. Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test. 2002; 6(2):93-105.
    View in: PubMed
  56. Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP. Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ. J Womens Health Gend Based Med. 2001 Jul-Aug; 10(6):589-98.
    View in: PubMed
  57. Harris LN, Yang L, Liotcheva V, Pauli S, Iglehart JD, Colvin OM, Hsieh TS. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res. 2001 Jun; 7(6):1497-504.
    View in: PubMed
  58. Rhei E, Nixon AJ, Iglehart JD. Surgical management of high-risk patients. Breast Dis. 2001; 12:3-12.
    View in: PubMed
  59. Miron A, Schildkraut JM, Rimer BK, Winer EP, Sugg Skinner C, Futreal PA, Culler D, Calingaert B, Clark S, Kelly Marcom P, Iglehart JD. Testing for hereditary breast and ovarian cancer in the southeastern United States. Ann Surg. 2000 May; 231(5):624-34.
    View in: PubMed
  60. Lobenhofer EK, Huper G, Iglehart JD, Marks JR. Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ. 2000 Feb; 11(2):99-110.
    View in: PubMed
  61. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, Dewhirst M, Greenberg C. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000 Feb; 18(3):600-8.
    View in: PubMed
  62. Davis PL, Miron A, Andersen LM, Iglehart JD, Marks JR. Isolation and initial characterization of the BRCA2 promoter. Oncogene. 1999 Oct 28; 18(44):6000-12.
    View in: PubMed
  63. Lambers AR, Gumbs C, Ali S, Marks JR, Iglehart JD, Berchuck A, Futreal PA. Bcl10 is not a target for frequent mutation in human carcinomas. Br J Cancer. 1999 Jul; 80(10):1575-6.
    View in: PubMed
  64. Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis. J Clin Oncol. 1999 May; 17(5):1465-73.
    View in: PubMed
  65. Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol. 1999 Mar; 17(3):1040-6.
    View in: PubMed
  66. Clark S, Iglehart JD. Genetic counseling for breast cancer. Adv Surg. 1999; 33:199-215.
    View in: PubMed
  67. Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ. Overestimation of hereditary breast cancer risk. Ann Surg. 1998 Sep; 228(3):375-84.
    View in: PubMed
  68. Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 1998 Jul-Aug; 18(4C):2919-32.
    View in: PubMed
  69. Coveney E, Weltz CR, Greengrass R, Iglehart JD, Leight GS, Steele SM, Lyerly HK. Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg. 1998 Apr; 227(4):496-501.
    View in: PubMed
  70. Burke HB, Hoang A, Iglehart JD, Marks JR. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer. 1998 Mar 1; 82(5):874-7.
    View in: PubMed
  71. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer. 1998; 77(1):51-6.
    View in: PubMed
  72. Lo JY, Baker JA, Kornguth PJ, Iglehart JD, Floyd CE. Predicting breast cancer invasion with artificial neural networks on the basis of mammographic features. Radiology. 1997 Apr; 203(1):159-63.
    View in: PubMed
  73. Marks JR, Huper G, Vaughn JP, Davis PL, Norris J, McDonnell DP, Wiseman RW, Futreal PA, Iglehart JD. BRCA1 expression is not directly responsive to estrogen. Oncogene. 1997 Jan 9; 14(1):115-21.
    View in: PubMed
  74. Vaughn JP, Stekler J, Demirdji S, Mills JK, Caruthers MH, Iglehart JD, Marks JR. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res. 1996 Nov 15; 24(22):4558-64.
    View in: PubMed
  75. Hettasch JM, Bandarenko N, Burchette JL, Lai TS, Marks JR, Haroon ZA, Peters K, Dewhirst MW, Iglehart JD, Greenberg CS. Tissue transglutaminase expression in human breast cancer. Lab Invest. 1996 Nov; 75(5):637-45.
    View in: PubMed
  76. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. Cell cycle control of BRCA2. Cancer Res. 1996 Oct 15; 56(20):4590-4.
    View in: PubMed
  77. Davis P, Bazar K, Huper G, Lozano G, Marks J, Iglehart JD. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene. 1996 Sep 19; 13(6):1315-22.
    View in: PubMed
  78. Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR, Berchuck A. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res. 1996 Sep; 2(9):1571-5.
    View in: PubMed
  79. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996 Jun; 13(2):238-40.
    View in: PubMed
  80. Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, Marks JR. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ. 1996 Jun; 7(6):711-5.
    View in: PubMed
  81. Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene. 1996 May 2; 12(9):2003-9.
    View in: PubMed
  82. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, Iglehart JD, Deininger PL, McDonnell DP. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem. 1995 Sep 29; 270(39):22777-82.
    View in: PubMed
  83. Vaughn JP, Iglehart JD, Demirdji S, Davis P, Babiss LE, Caruthers MH, Marks JR. Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc Natl Acad Sci U S A. 1995 Aug 29; 92(18):8338-42.
    View in: PubMed
  84. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg. 1995 Aug; 222(2):155-62.
    View in: PubMed
  85. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg. 1995 Jun; 221(6):677-83; discussion 683-4.
    View in: PubMed
  86. Weigel RJ, Crooks DL, Iglehart JD, deConinck EC. Quantitative analysis of the transcriptional start sites of estrogen receptor in breast carcinoma. Cell Growth Differ. 1995 Jun; 6(6):707-11.
    View in: PubMed
  87. Iglehart JD, Kerns BJ, Huper G, Marks JR. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat. 1995 Jun; 34(3):253-63.
    View in: PubMed
  88. Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 1995 Jan 1; 55(1):51-6.
    View in: PubMed
  89. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart JD, Marks JR. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ. 1994 Dec; 5(12):1301-7.
    View in: PubMed
  90. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns BJ, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994 Apr; 219(4):332-41.
    View in: PubMed
  91. Futreal PA, Cochran C, Marks JR, Iglehart JD, Zimmerman W, Barrett JC, Wiseman RW. Mutation analysis of the THRA1 gene in breast cancer: deletion/fusion of the gene to a novel sequence on 17q in the BT474 cell line. Cancer Res. 1994 Apr 1; 54(7):1791-4.
    View in: PubMed
  92. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst. 1994 Mar 2; 86(5):372-8.
    View in: PubMed
  93. Pence JC, Kerns BJ, Dodge RK, Iglehart JD. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg. 1993 Dec; 128(12):1382-90.
    View in: PubMed
  94. Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfied LJ. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol. 1993 Nov; 6(6):673-8.
    View in: PubMed
  95. Anscher MS, Jones P, Prosnitz LR, Blackstock W, Hebert M, Reddick R, Tucker A, Dodge R, Leight G, Iglehart JD, et al. Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg. 1993 Jul; 218(1):22-8.
    View in: PubMed
  96. Berend ME, Sullivan DC, Kornguth PJ, Skinner CS, Ost A, Iglehart JD, Skinner MA. The natural history of mammographic calcifications subjected to interval follow-up. Arch Surg. 1992 Nov; 127(11):1309-13.
    View in: PubMed
  97. Huper G, Marks JR, Wiener JR, Iglehart JD. Relative promoter activity in human mammary epithelial cells assayed by transient expression. In Vitro Cell Dev Biol. 1992 Nov-Dec; 28A(11-12):730-4.
    View in: PubMed
  98. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992 Jul; 40(7):1047-51.
    View in: PubMed
  99. Deutsch MA, Pence JC, Kerns BJ, Plate CA, Kinney R, Gooch G, Iglehart JD, Bast RC. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer. 1992 Jun 15; 69(12):2894-904.
    View in: PubMed
  100. Futreal PA, Söderkvist P, Marks JR, Iglehart JD, Cochran C, Barrett JC, Wiseman RW. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res. 1992 May 1; 52(9):2624-7.
    View in: PubMed
  101. Herzberg AJ, Kerns BJ, Honkanen FA, Pence JC, Iglehart JD, Kinney RB. DNA ploidy and proliferation index of soft tissue sarcomas determined by image cytometry of fresh frozen tissue. Am J Clin Pathol. 1992 May; 97(5 Suppl 1):S29-37.
    View in: PubMed
  102. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A. 1992 Apr 15; 89(8):3439-42.
    View in: PubMed
  103. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC, Marks JR. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992 Mar 15; 52(6):1622-7.
    View in: PubMed
  104. Davidoff AM, Pence JC, Shorter NA, Iglehart JD, Marks JR. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene. 1992 Jan; 7(1):127-33.
    View in: PubMed
  105. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD. p53 alterations in all stages of breast cancer. J Surg Oncol. 1991 Dec; 48(4):260-7.
    View in: PubMed
  106. Pence JC, Kizilbash AM, Kerns BJ, Marks JR, Iglehart JD. Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J Surg Oncol. 1991 Sep; 48(1):11-20.
    View in: PubMed
  107. Davidoff AM, Herndon JE, Glover NS, Kerns BJ, Pence JC, Iglehart JD, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery. 1991 Aug; 110(2):259-64.
    View in: PubMed
  108. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A. 1991 Jun 1; 88(11):5006-10.
    View in: PubMed
  109. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991 Jun 1; 51(11):2979-84.
    View in: PubMed
  110. Davidoff AM, Kerns BJ, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res. 1991 May 15; 51(10):2605-10.
    View in: PubMed
  111. Reynolds SH, Anna CK, Brown KC, Wiest JS, Beattie EJ, Pero RW, Iglehart JD, Anderson MW. Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci U S A. 1991 Feb 15; 88(4):1085-9.
    View in: PubMed
  112. Kerns BJ, Pence JC, Huper G, Kinney RB, Iglehart JD. c-erbB-2 expression in breast cancer detected by immunoblotting and immunohistochemistry. J Histochem Cytochem. 1990 Dec; 38(12):1823-30.
    View in: PubMed
  113. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res. 1990 Oct 15; 50(20):6701-7.
    View in: PubMed
  114. Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, Iglehart JD, Moore J, Gockerman J, et al. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 1; 66(3):431-6.
    View in: PubMed
  115. Skinner MA, Vollmer R, Huper G, Abbott P, Iglehart JD. Loss of heterozygosity for genes on 11p and the clinical course of patients with lung carcinoma. Cancer Res. 1990 Apr 15; 50(8):2303-6.
    View in: PubMed
  116. Burton GV, Hart LL, Leight GS, Iglehart JD, McCarty KS, Cox EB. Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer. 1989 Jun 1; 63(11):2088-92.
    View in: PubMed
  117. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 1989 Feb; 4(2):145-51.
    View in: PubMed
  118. Everitt JI, Boreiko CJ, Mangum JB, Martin JT, Iglehart JD, Hesterberg TW. Development of a tracheal implant xenograft model to expose human bronchial epithelial cells to toxic gases. Toxicol Pathol. 1989; 17(3):465-73.
    View in: PubMed
  119. Skinner MA, Swain M, Simmons R, McCarty KS, Sullivan DC, Iglehart JD. Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features. Ann Surg. 1988 Aug; 208(2):203-8.
    View in: PubMed
  120. Hesterberg TW, Boreiko CJ, Maness SC, Iglehart JD, Mangum JB, Everitt JI. Carcinogen-induced unscheduled DNA synthesis in xenotransplanted human tracheobronchial epithelium: comparison with rat tracheal epithelium. Carcinogenesis. 1988 Mar; 9(3):467-72.
    View in: PubMed
  121. Thiel K, Genovesi EV, Iglehart JD, Bolognesi DP, Weinhold KJ. Loss of tumorigenicity following in vitro MuLV infection is associated with induction of peritoneal natural killer cell activity. Adv Exp Med Biol. 1988; 239:169-83.
    View in: PubMed
  122. Burton GV, Cox EB, Leight GS, Prosnitz LR, Iglehart JD, Olsen GA, Seigler HF, Hart LL. Inflammatory breast carcinoma. Effective multimodal approach. Arch Surg. 1987 Nov; 122(11):1329-32.
    View in: PubMed
  123. Hesterberg TW, Maness SC, Iglehart JD, Sanchez JH, Boreiko CJ. Subpopulations of human bronchial epithelial cells in culture respond heterogeneously to 12-O-tetradecanoylphorbol-13-acetate (TPA) and other modulators of differentiation. Carcinogenesis. 1987 Oct; 8(10):1511-5.
    View in: PubMed
  124. Vollmer RT, Shelburne JD, Iglehart JD. Intercellular junctions and tumor stage in small cell carcinoma of the lung. Hum Pathol. 1987 Jan; 18(1):22-7.
    View in: PubMed
  125. Iglehart JD, Mansback C, Postlethwait R, Roberts L, Ruth W. Pancreaticobronchial fistula. Case report and review of the literature. Gastroenterology. 1986 Mar; 90(3):759-63.
    View in: PubMed
  126. Iglehart JD, Wolfe WG, Vernon WB, Shelburne JD, Sabiston DC. Electron microscopy in selection of patients with small cell carcinoma of the lung for medical versus surgical therapy. J Thorac Cardiovasc Surg. 1985 Sep; 90(3):351-60.
    View in: PubMed
  127. Iglehart JD, Ferguson BJ, Shingleton WW, Sabiston DC, Silva JS, Fetter BF, McCarty KS. An ultrastructural analysis of breast carcinoma presenting as isolated axillary adenopathy. Ann Surg. 1982 Jul; 196(1):8-13.
    View in: PubMed
  128. Iglehart JD, Warzynski MJ, Montelaro RC, Bolognesi DP, Sabiston DC, Wolfe WG. Function of the secretory immune system in bronchogenic carcinoma. Immunoglobulin A levels in respiratory secretions. J Thorac Cardiovasc Surg. 1981 Jul; 82(1):63-9.
    View in: PubMed
  129. Langlois AJ, Holder WD, Iglehart JD, Nelson-Rees WA, Wells SA, Bolognesi DP. Morphological and biochemical properties of a new human breast cancer cell line. Cancer Res. 1979 Jul; 39(7 Pt 1):2604-13.
    View in: PubMed
  130. Iglehart JD, Montelaro RC, Bolognesi DP, Sabiston DC, Wolfe WG. Response of the secretory immune system to bronchogenic carcinoma of the lung. Surg Forum. 1979; 30:118-9.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Iglehart's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_